GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40823)

  • GC91430 structure
    GC91430RAD150
    CAS: 1208070-53-4
    Purity: >95.00%

    RAD150 est un modulateur sélectif des récepteurs aux androgènes non stéroïdiens (IC50 = 130 nM) et un dérivé d'esters benzoate du modulateur sélectif des récepteurs aux androgènes (SARM) RAD140.

  • GC91431 structure
    GC91431WDR5-MYC Probe 12
    Purity: >98.00%

    La sonde WDR5-MYC 12 est un inhibiteur de l'interaction protéine-protéine entre le facteur de transcription maître Myc et le domaine répété en WD 5 (WDR5 ; IC50 = 0,39 µM).

  • GC91432 structure
    GC91432CAY10799
    CAS: 1423622-48-3
    Purity: >98.00%

    CAY10799 est un précurseur dans la synthèse de ligands et de sondes fluorescentes spécifiques à l'antigène membranaire spécifique de la prostate (PSMA) qui ont été utilisés pour détecter le PSMA dans les cellules LNCaP et PC3.

  • GC91434 structure
    GC91434N-ethyl Perfluorooctanesulfonamide
    CAS: 4151-50-2
    Purity: >85.00%

    N-éthyl perfluorooctanesulfonamide (N-éthyl FOSA) est une substance perfluoroalkyle (PFAS) et un insecticide.

  • GC91435 structure
    GC91435YCH1899
    Purity: >98.00%

    YCH1899 est un inhibiteur de la poly(ADP-ribose) polymérase 1 (PARP1) et PARP2 (IC50s = 1 Il est sélectif pour PARP1 et PARP2 par rapport à PARP3, -4, -5A, -5B, -6, -7, -10 et -12 (IC50s = 1-14.1 nM).

  • GC91438 structure
    GC91438N-ethyl Perfluorooctanesulfonamidoethanol
    CAS: 1691-99-2
    Purity: >90.00%

    N-éthyl Perfluorooctanesulfonamidoéthanol (N-éthyl FOSE) est une substance perfluoroalkyle (PFAS).

  • GC91448 structure
    GC91448Fumonisin B4
    CAS: 136379-60-7
    Purity: >98.00%

    La fumonisine B4 (FB4) est une mycotoxine qui a été trouvée dans F. verticillioides.

  • GC91449 structure
    GC91449Ipamorelin (acetate)
    Purity: >98.00%

    Ipamorelin est un agoniste du récepteur GHS 1a (GHS-R1a) et un sécrétagogue d'hormone de croissance pentapeptide (GHS).

  • GC91450 structure
    GC91450De-Boc-Cabazitaxel
    CAS: 1638286-64-2
    Purity: >95.00%

    De-Boc-Cabazitaxel est une impureté potentielle dans les préparations commerciales du taxane semi-synthétique cabazitaxel.

  • GC91453 structure
    GC91453ALC-0315 N-oxide
    Purity: >98.00%

    L'ALC-0315 N-oxyde est une impureté potentielle dans les préparations commerciales du lipide amino cationique ionisable ALC-0315.

  • GC91460 structure
    GC91460CYN 154806 (trifluoroacetate salt)
    Purity: >90.00%

    CYN 154806 est un antagoniste cyclique du récepteur de la somatostatine 2 (SST2) sous forme de peptide (IC50 = 2,62 nM).

  • GC91472 structure
    GC91472Tat-Gap 19 (trifluoroacetate salt)
    Purity: >95.00%

    Tat-Gap 19 est un inhibiteur peptidique des hémicanaux de connexine43 (Cx43).

  • GC91480 structure
    GC91480Exendin-4 (3-39) amide (trifluoroacetate salt)
    Purity: >90.00%

    Exendin-4 (3-39) amide est un agoniste du récepteur de peptide 1 similaire au glucagon (GLP-1R) et un métabolite actif d'exendin-4 (48-86) amide.

  • GC91483 structure
    GC91483DPPD-Q
    CAS: 3421-08-7
    Purity: >95.00%

    DPPD-Q is an oxidized derivative of the antioxidant and substituted p-phenylenediamine DPPD.

  • GC91488 structure
    GC91488Proxymetacaine (hydrochloride)
    CAS: 5875-06-9
    Purity: >98.00%

    Proxymetacaine is an anesthetic.

  • GC91489 structure
    GC91489Chondroitin Sulfate A (sodium salt)
    CAS: 9082-07-9
    Purity: >98.00%

    Chondroitin sulfate A (CSA) is a glycosaminoglycan.

  • GC91492 structure
    GC91492Propiverine N-oxide
    CAS: 111071-96-6
    Purity: >95.00%

    Propiverine N-oxide is an active metabolite of the muscarinic acetylcholine receptor antagonist propiverine .

  • GC91493 structure
    GC91493Semaglutide Side Chain
    CAS: 1118767-16-0
    Purity: >98.00%

    Semaglutide side chain is a synthetic intermediate.

  • GC91494 structure
    GC914946-Deoxy-8-O-methylrabelomycin
    CAS: 117620-87-8
    Purity: >95.00%

    6-Deoxy-8-O-methylrabelomycin is an anthraquinone that has been found in Pseudonocardia with antiparasitic and antibiotic activities.

  • GC91497 structure
    GC91497EB 47 (hydrochloride)
    CAS: 1190332-25-2
    Purity: >98.00%

    EB 47 is an inhibitor of poly(ADP-ribose) polymerase 1 (PARP1; IC50 = 45 nM) and a dual site inhibitor of tankyrase 2 (TNKS2; IC50 = 45 nM).

  • GC91499 structure
    GC91499Voriconazole-d3 N-oxide
    CAS: 1217851-84-7
    Purity: >99.00%

    Voriconazole-d3 N-oxide is intended for use as an internal standard for the quantification of voriconazole N-oxide by GC- or LC-MS.

  • GC91506 structure
    GC91506Bayer 18
    CAS: 1251752-12-1
    Purity: >98.00%

    Bayer 18 is a tyrosine kinase 2 (TYK2) inhibitor (IC50 = 18.7 nM).

  • GC91507 structure
    GC91507CP 93,129
    CAS: 127792-75-0
    Purity: >95.00%

    CP 93,129 is an agonist of the serotonin (5-HT) receptor subtype 5-HT1B.

  • GC91514 structure
    GC91514para-methoxy-2-amino Benzamidoxime
    CAS: 1359828-78-6
    Purity: >95.00%

    para-methoxy-2-amino-Benzamidoxime (PMA) is a fluorescent and reactive probe for ketones.